Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ILKN421H |
| Trade Name | |
| Synonyms | ILKN-421H|ILKN 421H |
| Drug Descriptions |
ILKN421H is a lipid nanoparticle-formulated mRNA encoding an IL2Rbeta-gamma-selective IL2v, which potentially induces CD8-positive T-cell and NK cell proliferation and antitumor immune activity (J Clin Oncol 2026 44: 16_suppl, 8556). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ILKN421H | ILKN421H | 0 | 0 |
| ILKN421H + Pembrolizumab | ILKN421H Pembrolizumab | 0 | 1 |